Obstetrics and Gynecology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study of Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to collect vaginal and endometrial cell samples to study endometrial cancer.

2. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) alone and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).

3. Mayo Clinic Umbilical and Placental Tissues Biobank

   Rochester, Minn.

   The purpose of this study is to collect paired maternal and umbilical cord blood samples that can be processed for various traits in the blood, including serum, DNA, RNA and cells. The long term goal of this project is to start an Umbilical and Placental Tissues Biobank, which will operate in parallel to the Mayo Clinic Biobank. In future studies, we may use the serum, DNA and RNA obtained from cord blood and your blood to understand health and disease.

4. A Study to Assess Maternal and Fetal Outcomes in Pregnancy with Type 1 Diabetes Mellitus and Controls

   Rochester, Minn.

   The purpose of this study is to retrospectively and prospectively compare maternal and fetal/newborn clinical outcomes in age-matched pregnant patients with T1D and healthy controls and to assess the relationship between glycemic variability and pregnancy outcomes in the current era.

5. A Study to Evaluate Fertility, Sexual Function, and Endothelial Health in Premenopausal Women with Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate how advancing stages of chronic kidney disease (CKD) may impact the hypothalamic-pituitary-gonadal axis,and how alterations in sex hormones and menstrual cycles correlate with changes in endothelial health and sexual function before and after transplant.

6. Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   This randomized phase II trial studies how well ATR kinase inhibitor M6620 (M6620) and gemcitabine hydrochloride work compared to standard treatment with gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). ATR kinase inhibitor M6620 may stop the growth of tumor cells by blocking an enzyme needed for cell growth, and may also help gemcitabine hydrochloride work better. Gemcitabine hydrochloride is a drug used in chemotherapy that works to stop the growth of tumor cells by blocking cells from growing and repairing themselves, causing them to die. It is not yet known whether adding ATR kinase inhibitor M6620 to standard treatment with gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.

7. A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in 2 groups of patients with peritoneal carcinomatosis (PC), either due to primary ovarian, uterine, or gastric carcinoma (Arm 1) or to primary colorectal carcinoma (Arm 2), based on treatment-related adverse events reported by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.  

8. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

9. Understanding the Biology of Uterine Smooth Muscle

   Rochester, Minn.

   This study will investigate the biology of uterine smooth muscle cells and particularly explore the commonalities it has with smooth muscle cells of the airway.

10. A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer

    Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

    The purpose of this study is to evaluate the safety and tolerability of the combination of DS-8201a in combination with olaparib, and to determine the recommended phase 2 dose (RP2D) 1.1.2 To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with uterine serous carcinoma.